Cytokinetics, Incorporated Company Profile (NASDAQ:CYTK)

About Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics, Incorporated logoCytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYTK
  • CUSIP: N/A
  • Web: www.cytokinetics.com
Capitalization:
  • Market Cap: $767.43 million
  • Outstanding Shares: 53,666,000
Average Prices:
  • 50 Day Moving Avg: $13.51
  • 200 Day Moving Avg: $13.58
  • 52 Week Range: $8.69 - $17.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.58
  • P/E Growth: -0.38
Sales & Book Value:
  • Annual Revenue: $99.39 million
  • Price / Sales: 7.83
  • Book Value: $3.27 per share
  • Price / Book: 4.43
Profitability:
  • EBIDTA: ($10,030,000.00)
  • Net Margins: -16.00%
  • Return on Equity: -14.15%
  • Return on Assets: -6.81%
Debt:
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 10.21%
  • Quick Ratio: 10.21%
Misc:
  • Average Volume: 471,336 shs.
  • Beta: 1.97
  • Short Ratio: 7.34
 

Frequently Asked Questions for Cytokinetics, Incorporated (NASDAQ:CYTK)

What is Cytokinetics, Incorporated's stock symbol?

Cytokinetics, Incorporated trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics, Incorporated's earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The company earned $3.05 million during the quarter, compared to the consensus estimate of $5.28 million. Cytokinetics, Incorporated had a negative return on equity of 14.15% and a negative net margin of 16.00%. View Cytokinetics, Incorporated's Earnings History.

When will Cytokinetics, Incorporated make its next earnings announcement?

Cytokinetics, Incorporated is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Cytokinetics, Incorporated.

Where is Cytokinetics, Incorporated's stock going? Where will Cytokinetics, Incorporated's stock price be in 2017?

10 equities research analysts have issued 1-year price targets for Cytokinetics, Incorporated's stock. Their forecasts range from $15.00 to $26.00. On average, they anticipate Cytokinetics, Incorporated's share price to reach $22.00 in the next year. View Analyst Ratings for Cytokinetics, Incorporated.

What are analysts saying about Cytokinetics, Incorporated stock?

Here are some recent quotes from research analysts about Cytokinetics, Incorporated stock:

  • 1. Cantor Fitzgerald analysts commented, "A secondary analysis of the expansion phase of the Phase II COSMIC-HF study showed consistent results for omecamtiv mecarbil among patients with either ischemic or non-ischemic heart failure (64% and 36% of the trial population, respectively)." (9/18/2017)
  • 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
  • 3. Cowen and Company analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)
  • 4. Rodman & Renshaw analysts commented, "Our price target is based on our clinical net present value (NPV) model, which is currently driven by omecamtiv mecarbil ($19.77/share) and modest contributions from tirasemtiv ($4.26/share) and CK-107 ($1.05/share). We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/23/2017)
  • 5. HC Wainwright analysts commented, "We have adjusted our 2017 estimates downward accordingly. The company had a net loss of $4.3M in 4Q16, or ($0.81) per share based on shares adjusted for the 1-for-10 reverse split effective on February 27. 2016. The loss was lower than our estimate of $4.9M due to improved expense management. For the fiscal year 2016, TearLab had $28M in revenue, representing 11% growth over that of 2015, and $19.9M in net loss. In our view, the softened growth rate in the Flex program and in international markets could continue in 2017. Therefore, we currently project a conservative low single-digit growth in revenue in 2017. Our valuation of the company has decreased from $140M to $105M. Excluding debt, our estimated market value of the firm is $79M. Assuming 6.5M shares outstanding at the end of 2017, we project a 12-month price target of $12 per share. Our previous price target was $2 before the reverse split. Importantly, TearLab has begun a process to explore strategic alternatives, which does not preclude a sale of the company." (3/13/2017)

Who are some of Cytokinetics, Incorporated's key competitors?

Who are Cytokinetics, Incorporated's key executives?

Cytokinetics, Incorporated's management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Independent Chairman of the Board
  • Robert I. Blum, President, Chief Executive Officer, Director
  • Ching Jaw, Chief Financial Officer, Senior Vice President
  • Sharon A. Barbari, Executive Vice President - Finance
  • Fady I. Malik M.D. Ph.D., Executive Vice President - Research and Development
  • Peter S. Roddy, Senior Vice President, Chief Accounting Officer
  • David W. Cragg, Senior Vice President - Human Resources
  • Bonnie A. Charpentier Ph.D., Senior Vice President - Regulatory Affairs and Compliance
  • Bradley Paul Morgan Ph.D., Senior Vice President - Research and Non-Clinical Development
  • Elisabeth Schnieders Ph.D., Senior Vice President - Business Development

Who owns Cytokinetics, Incorporated stock?

Cytokinetics, Incorporated's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (9.60%), Vanguard Group Inc. (6.47%), Janus Henderson Group PLC (5.00%), State Street Corp (3.12%), Citigroup Inc. (1.66%) and Wasatch Advisors Inc. (1.43%). Company insiders that own Cytokinetics, Incorporated stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics, Incorporated.

Who sold Cytokinetics, Incorporated stock? Who is selling Cytokinetics, Incorporated stock?

Cytokinetics, Incorporated's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wasatch Advisors Inc., OxFORD Asset Management LLP, Trexquant Investment LP, Gotham Asset Management LLC, Airain ltd, Fortaleza Asset Management Inc. and Virtu KCG Holdings LLC. Company insiders that have sold Cytokinetics, Incorporated stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics, Incorporated.

Who bought Cytokinetics, Incorporated stock? Who is buying Cytokinetics, Incorporated stock?

Cytokinetics, Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Vanguard Group Inc., State Street Corp, Acadian Asset Management LLC, Principal Financial Group Inc., Bank of New York Mellon Corp, Laurion Capital Management LP and Ameriprise Financial Inc.. View Insider Buying and Selling for Cytokinetics, Incorporated.

How do I buy Cytokinetics, Incorporated stock?

Shares of Cytokinetics, Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics, Incorporated's stock price today?

One share of Cytokinetics, Incorporated stock can currently be purchased for approximately $14.50.


MarketBeat Community Rating for Cytokinetics, Incorporated (NASDAQ CYTK)
Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  408
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics, Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cytokinetics, Incorporated (NASDAQ:CYTK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (51.72% upside)

Analysts' Ratings History for Cytokinetics, Incorporated (NASDAQ:CYTK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017HC WainwrightReiterated RatingBuy$26.00LowView Rating Details
9/18/2017Cantor FitzgeraldReiterated RatingBuy$21.00LowView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$22.00LowView Rating Details
8/4/2017Cowen and CompanyReiterated RatingBuy$19.00LowView Rating Details
7/31/2017Morgan StanleyInitiated CoverageOverweight -> Overweight$24.00HighView Rating Details
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00MediumView Rating Details
2/17/2017FBR & CoReiterated RatingOutperform$24.00N/AView Rating Details
2/17/2017Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$22.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$16.00 -> $14.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Cytokinetics, Incorporated (NASDAQ:CYTK)
Earnings by Quarter for Cytokinetics, Incorporated (NASDAQ:CYTK)
Earnings History by Quarter for Cytokinetics, Incorporated (NASDAQ CYTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017($0.64)N/AView Earnings Details
8/2/2017Q2 2017($0.57)($0.60)$5.28 million$3.05 millionViewListenView Earnings Details
2/16/2017Q416($0.39)$0.16$14.10 million$33.14 millionViewListenView Earnings Details
10/27/2016Q3($0.27)$0.74$6.67 million$59.05 millionViewListenView Earnings Details
7/28/2016Q2($0.28)($0.29)$7.80 million$5.80 millionViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)$8.14 million$8.42 millionViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
7/29/2015Q2($0.28)($0.27)$4.00 million$6.54 millionViewListenView Earnings Details
4/30/2015Q1($0.08)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)$6.50 million$9.42 millionViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytokinetics, Incorporated (NASDAQ:CYTK)
2017 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.66)($0.66)($0.66)
Q3 20171($0.70)($0.70)($0.70)
Q4 20171($0.75)($0.75)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytokinetics, Incorporated (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cytokinetics, Incorporated (NASDAQ:CYTK)
Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 71.51%
Insider Trades by Quarter for Cytokinetics, Incorporated (NASDAQ:CYTK)
Institutional Ownership by Quarter for Cytokinetics, Incorporated (NASDAQ:CYTK)
Insider Trades by Quarter for Cytokinetics, Incorporated (NASDAQ:CYTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2017Caryn Gordon McdowellInsiderSell10,131$14.60$147,912.60View SEC Filing  
9/1/2017Robert I BlumCEOSell5,000$14.71$73,550.00View SEC Filing  
8/31/2017Bradley Paul MorganSVPSell118,330$15.00$1,774,950.00View SEC Filing  
8/31/2017Santo J CostaDirectorSell5,000$15.00$75,000.00View SEC Filing  
8/29/2017Santo J CostaDirectorSell5,000$14.00$70,000.00View SEC Filing  
8/8/2017Caryn Gordon McdowellInsiderSell11,348$12.47$141,509.56View SEC Filing  
8/1/2017Robert I BlumCEOSell5,000$13.79$68,950.00View SEC Filing  
7/3/2017Robert I BlumCEOSell5,000$12.14$60,700.00View SEC Filing  
6/1/2017Robert I BlumCEOSell5,000$13.62$68,100.00View SEC Filing  
12/29/2016Fady Ibraham MalikEVPSell5,633$12.36$69,623.88View SEC Filing  
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cytokinetics, Incorporated (NASDAQ:CYTK)
Latest Headlines for Cytokinetics, Incorporated (NASDAQ:CYTK)
Source:
DateHeadline
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 24 at 2:46 PM
globenewswire.com logoCompany Earns $10 Million Milestone Payment from Amgen
globenewswire.com - September 20 at 6:31 PM
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - September 20 at 5:10 PM
streetinsider.com logoCytokinetics (CYTK) Reports Dosing of First Patient in Japan in GALACTIC-HF Phase 3 Clinical Trial - StreetInsider.com
www.streetinsider.com - September 19 at 10:45 PM
finance.yahoo.com logoCytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
finance.yahoo.com - September 19 at 5:43 PM
streetinsider.com logoCytokinetics (CYTK) Presents Additional Results From COSMIC-HF at HFSA - StreetInsider.com
www.streetinsider.com - September 18 at 10:42 PM
finance.yahoo.com logoCytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting
finance.yahoo.com - September 18 at 5:41 PM
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - September 18 at 9:40 AM
americanbankingnews.com logoNeedham & Company LLC Reaffirms Buy Rating for Cytokinetics, Incorporated (CYTK)
www.americanbankingnews.com - September 17 at 8:48 AM
nasdaq.com logoOptions Traders Expect Huge Moves in Cytokinetics (CYTK) Stock - Nasdaq
www.nasdaq.com - September 16 at 5:16 PM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Cytokinetics (CYTK) Stock
finance.yahoo.com - September 15 at 6:08 PM
seekingalpha.com logoCytokinetics (CYTK) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 7:00 PM
finance.yahoo.com logoCytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting
finance.yahoo.com - September 11 at 6:23 PM
americanbankingnews.com logoCaryn Gordon Mcdowell Sells 10,131 Shares of Cytokinetics, Incorporated (CYTK) Stock
www.americanbankingnews.com - September 8 at 8:20 PM
finance.yahoo.com logoETFs with exposure to Cytokinetics, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 5:53 PM
finance.yahoo.com logoCytokinetics to Present at September Investor Conferences
finance.yahoo.com - September 5 at 7:18 PM
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - September 3 at 3:58 PM
americanbankingnews.com logoRobert I. Blum Sells 5,000 Shares of Cytokinetics, Incorporated (CYTK) Stock
www.americanbankingnews.com - September 1 at 10:24 PM
americanbankingnews.com logoInsider Selling: Cytokinetics, Incorporated (CYTK) Director Sells 5,000 Shares of Stock
www.americanbankingnews.com - September 1 at 10:24 PM
americanbankingnews.com logoBradley Paul Morgan Sells 118,330 Shares of Cytokinetics, Incorporated (CYTK) Stock
www.americanbankingnews.com - September 1 at 10:22 PM
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Director Sells $70,000.00 in Stock
www.americanbankingnews.com - August 30 at 10:20 PM
finance.yahoo.com logoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : August 29, 2017
finance.yahoo.com - August 29 at 6:09 PM
finance.yahoo.com logoETFs with exposure to Cytokinetics, Inc. : August 21, 2017
finance.yahoo.com - August 22 at 11:25 PM
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - August 17 at 6:50 PM
bizjournals.com logoStock Performance Review on Biotech Industry -- Blueprint Medicines, Calithera Biosciences, Concordia Intl., and Cytokinetics
www.bizjournals.com - August 14 at 6:06 PM
americanbankingnews.com logoCytokinetics, Incorporated (NASDAQ:CYTK) Insider Sells $141,509.56 in Stock
www.americanbankingnews.com - August 10 at 10:46 PM
finance.yahoo.com logoCytokinetics, Inc. :CYTK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 7:01 PM
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - August 7 at 8:38 PM
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 5 at 2:38 PM
finance.yahoo.com logoFeatured Company News - Cytokinetics Announces Positive Results for Phase-2 Clinical Trial of Omecamtiv Mecabril in Japanese Patients with Heart Failure
finance.yahoo.com - August 4 at 6:01 PM
finance.yahoo.com logoCytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : August 4, 2017
finance.yahoo.com - August 4 at 6:01 PM
americanbankingnews.com logoCytokinetics, Incorporated (NASDAQ:CYTK) Receives "Buy" Rating from Cowen and Company
www.americanbankingnews.com - August 4 at 1:48 PM
americanbankingnews.com logoCytokinetics, Incorporated (CYTK) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - August 3 at 8:32 PM
streetinsider.com logoCytokinetics (CYTK) Reports Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients ... - StreetInsider.com
www.streetinsider.com - August 3 at 4:40 AM
globenewswire.com logoCytokinetics, Inc. Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 3 at 4:40 AM
finance.yahoo.com logoEdited Transcript of CYTK earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 4:40 AM
americanbankingnews.com logoCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 5,000 Shares
www.americanbankingnews.com - August 2 at 10:30 PM
finance.yahoo.com logoCytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients With Heart Failure
finance.yahoo.com - August 2 at 6:37 PM
finance.yahoo.com logoInvestor Network: Cytokinetics, Incorporated to Host Earnings Call
finance.yahoo.com - August 2 at 6:37 PM
finance.yahoo.com logoCytokinetics, Inc. Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 6:37 PM
finance.yahoo.com logoCytokinetics reports 2Q loss
finance.yahoo.com - August 2 at 6:37 PM
americanbankingnews.com logo$5.28 Million in Sales Expected for Cytokinetics, Incorporated (NASDAQ:CYTK) This Quarter
www.americanbankingnews.com - August 1 at 11:26 AM
finance.yahoo.com logoCytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : July 31, 2017
finance.yahoo.com - July 31 at 10:38 PM
americanbankingnews.com logoCytokinetics, Incorporated (NASDAQ:CYTK) Now Covered by Morgan Stanley
www.americanbankingnews.com - July 31 at 11:11 AM
americanbankingnews.com logo-$0.66 Earnings Per Share Expected for Cytokinetics, Incorporated (CYTK) This Quarter
www.americanbankingnews.com - July 30 at 7:43 AM
finance.yahoo.com logoCytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis
finance.yahoo.com - July 27 at 6:05 PM
finance.yahoo.com logoCytokinetics to Announce Second Quarter Results on August 2, 2017
finance.yahoo.com - July 26 at 6:18 PM
americanbankingnews.com logoCytokinetics, Incorporated (NASDAQ:CYTK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 17 at 8:26 PM
finance.yahoo.com logoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : July 17, 2017
finance.yahoo.com - July 17 at 6:37 PM
americanbankingnews.com logoCytokinetics, Incorporated (NASDAQ:CYTK) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - July 16 at 3:22 PM

Social

Chart

Cytokinetics, Incorporated (CYTK) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff